MyCural raises bridge round to advance cancer drug development

MyCural Therapeutics, that has been part of NOME since the start of the year, has secured a bridge round to accelerate the development of its drug candidates targeting high-risk cancers.

Founded in 2022 by researchers from Karolinska Institutet, Linköping University, and Uppsala University, MyCural is focused on inhibiting the MYC oncoprotein — a key driver of many aggressive tumours that has long been considered “undruggable.” By designing small molecules that selectively bind to MYC in tumour cell lines, the company is paving the way for new therapies that could benefit patients with limited treatment options today.

The new bridge round strengthens MyCural’s position as it advances development and prepares for the next phase of its journey - an autumn funding round that will propel them towards first-in-human trials.